Related Experiment Videos
PCV chemotherapy for recurrent glioblastoma multiforme.
A C Kappelle1, T J Postma, M J Taphoorn
1Departments of Neurology and Medical Oncology, University Hospital Vrije Universiteit, Amsterdam, The Netherlands.
Neurology
|January 10, 2001
Summary
Procarbazine, lomustine, and vincristine (PCV) chemotherapy showed limited efficacy in recurrent glioblastoma multiforme. Younger patients with better performance status experienced longer survival, indicating potential prognostic factors.
Area of Science:
- Neuro-oncology
- Clinical Pharmacology
- Cancer Chemotherapy
Background:
- Recurrent glioblastoma multiforme (GBM) presents significant treatment challenges.
- Limited effective salvage chemotherapy options exist for recurrent GBM.
Purpose of the Study:
- To evaluate the efficacy and safety of procarbazine, lomustine, and vincristine (PCV) chemotherapy in patients with recurrent GBM.
- To identify prognostic factors influencing treatment outcomes.
Main Methods:
- A cohort of 63 patients with recurrent GBM received PCV chemotherapy.
- Outcomes assessed included objective response rate, time to progression (TTP), overall survival (OS), and toxicity.
- Prognostic factors such as age and Karnofsky Performance Status (KPS) were analyzed.
Main Results:
- Objective response rates were low: 3% complete response and 8% partial response.
- Stable disease was observed in 25% of patients.
- Median TTP was 13 weeks and median OS was 33 weeks.
- Younger age (<40 years) and higher KPS (>=90) were associated with improved TTP and OS.
- PCV chemotherapy was generally well-tolerated with manageable toxicity.
Conclusions:
- PCV chemotherapy demonstrates limited efficacy as a salvage treatment for recurrent GBM.
- Patient factors like age and performance status are critical prognostic indicators for survival in recurrent GBM.
- Further research into novel therapeutic strategies for recurrent GBM is warranted.